The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.本發明提供抗CD112(Nectin-2、PVRL2)、CD155(PVR)、Galectin-9、TIM-3及/或TIGIT之抑制劑,其用於治療血源癌症,詳言之急性骨髓白血病(AML)之方法中。此外,本發明提供包含抗CD112(Nectin-2、PVRL2)、CD155(PVR)、Galectin-9、TIM-3及/或TIGIT之抑制劑及CAR T細胞之醫藥組合物。本發明進一步提供包含抗CD112(Nectin-2、PVRL2)、CD155(PVR)、Galectin-9、TIM-3及/或TIGIT之抑制劑及能夠接合T細胞之抗體構築體之醫藥組合物。
